A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

  title={A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.},
  author={Gavin Giovannoni and Giancarlo Comi and S. D. Noam Cook and Kottil W. Rammohan and Peter Rieckmann and Per Soelberg S\orensen and Patrick Vermersch and Peter Chang and Anthony C. Hamlett and Bruno Musch and Steven J. Greenberg},
  journal={The New England journal of medicine},
  volume={362 5},
BACKGROUND Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis. METHODS We randomly assigned 1326 patients in an approximate 1:1:1 ratio to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for the… CONTINUE READING
Highly Influential
This paper has highly influenced 21 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 30 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 177 extracted citations

The Risk of Fracture in Patients With Multiple Sclerosis: The UK General Practice Research Database

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2011
View 9 Excerpts
Highly Influenced

Chemotherapeutics in the treatment of multiple sclerosis.

Therapeutic advances in neurological disorders • 2010
View 19 Excerpts
Highly Influenced

Cladribine tablets added to IFN-β in active relapsing MS

Neurology(R) neuroimmunology & neuroinflammation • 2018
View 5 Excerpts
Highly Influenced

Progressive Multiple Sclerosis

Springer International Publishing • 2018
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 17 references

Preferential depletion of lymphocyte sub - populations by cladribine in a phase III clinical trial in multiple sclerosis

GP Rice, M Filippi, G Comi

Emerging oral therapies for multiple sclerosis.

International journal of clinical practice • 2007

The role of CD 4 T cells in 1 . the pathogenesis of multiple sclerosis

D Franciotta, F Aloisi
Int Rev Neurobiol • 2007

Similar Papers

Loading similar papers…